Lenalidomide

(Revlimid®)

Revlimid®

Latest News

loading GIF

Drug updated on 4/17/2024

Dosage FormCapsule (oral; 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg)
Drug ClassThalidomide analogues
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of multiple myeloma (MM), in combination with dexamethasone.
  • Indicated for the treatment of MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT).
  • Indicated for the treatment of transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities.
  • Indicated for the treatment of mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.
  • Indicated for the treatment of previously treated follicular lymphoma (FL), in combination with a rituximab product.
  • Indicated for the treatment of previously treated marginal zone lymphoma (MZL), in combination with a rituximab product.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Lenalidomide is indicated for the treatment of multiple myeloma, particularly in combination with dexamethasone and ixazomib, where it has shown significantly longer progression-free survival compared to other treatments. It also shows potential benefits as a maintenance therapy in chronic lymphocytic leukemia by extending progression-free survival.
  • Eight systematic reviews/meta-analyses covered various indications for lenalidomide, including multiple myeloma, CLL, DLBCL, and lupus, among others.
  • In patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), lenalidomide monotherapy showed activity and tolerability. However, better responsiveness was observed specifically in patients of the non-GCB phenotype, indicating subgroup-specific efficacy.
  • For newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients, maintenance therapy with lenalidomide did not show significant benefit in overall survival, suggesting its limited role due to lack of clear survival benefits.
  • The studies highlighted that triplet therapies containing monoclonal antibodies are superior for treating cases of lenalidomide-refractory multiple myeloma, demonstrating its limited utility but highlighting the efficacy of mAb-containing regimens within this patient subgroup.
  • Despite thromboprophylaxis measures taken into account during clinical trial settings involving multiple myeloma patients on a regimen based on lenalidomide, there still exists a substantial risk associated with venous thromboembolism, calling out the need for further strategies to mitigate this risk, especially when dealing with high VTE risk regimens.

Product Monograph / Prescribing Information

Document TitleYearSource
Revlimid (lenalidomide) Prescribing Information.2023Bristol-Myers Squibb Company, Princeton, NJ

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines